The understanding of the biology of CRPC and the evidence that CRPC still remains driven by androgen receptor signaling led to the discovery of new therapeutic targets. In the last few years ...

"Unfortunately, most patients with advanced, metastatic disease who are treated with drugs to inhibit androgen signaling will ... the androgen receptor is encouraged to "go solo" in the cell.

Astrazeneca AB has divulged proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase cereblon unit coupled to an androgen receptor (AR) targeting moiety via a linker acting as AR ...

Given the link between CDK12 loss and castration resistance in human PCa, investigators analyzed androgen receptor (AR) ...

Pfizer announces positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC: New York Friday, October 11, 2024, 09:00 Hrs [IST] Pf ...

Among patients with metastatic hormone-sensitive prostate cancer (mHSPC), patients with de novo vs secondary mHSPC are more likely to progress to castration-resistant disease.

making it the only drug in the androgen receptor signalling inhibitor class for this indication. Non-metastatic CSPC refers to tumours that haven’t spread to other parts of the body and respond ...

Endothelin is a peptide hormone known for its vasoconstrictive effects. Researchers at University of Tsukuba used ...

Expression studies on thyroid tumors indicate that they express ER and possibly progesterone receptors and androgen receptors ... and evaluation of the signaling pathways by which estrogen ...

“Unfortunately, most patients with advanced, metastatic disease who are treated with drugs to inhibit androgen signaling will ... the androgen receptor is encouraged to “go solo” in the ...